Dermal Abyss is a project between researchers from the Massachusetts Institute of Technology (MIT) and Harvard Medical School. They developed three biosensing tattoo inks that can change color in response to changing (high or low) blood sugar or glucose, pH and sodium levels in men or women. Biosensing tattoo inks have replaced traditional tattoo inks. They monitored the random medical condition of the patients.
The Dermal Abyss (D-abyss) tattoo inks can read the concentration of sodium, pH and glucose levels in the interstitial fluid of the skin. They provide alternative options to monitor the health complications such as an electrolyte imbalance, alkalosis, acidosis, diabetes and hypertension. The Dermal Abyss (d-abyss) (biosensors, biosensitive inks) are less invasive.
Colors of the ink in the tattoo changes with respect to the change in the interstitial fluid. The color of the ink turns into "brown" color from "blue" color as blood sugar levels increases. The ink of the pH biosensor in the tattoo changes from "purple" color to "pink" color.
Biosensing tattoo inks are very useful to the insulin-dependent patients with diabetes as they need to check blood sugar levels with a finger prick testing (an invasive procedure), between four and ten times daily. Researchers have done the preliminary evaluation and biosensitive tattoo color inks are in the testing process. The leader of the project was Katia Canepa Vega, MIT's Media Lab.
A study by researchers shows a higher risk of heart failure in early-stage prostate cancer male patients who underwent androgen deprivation therapy (ADT). Researchers followed 7,637 men between 1998 and 2008, diagnosed with localized prostate cancer (cancer is contained within the prostate gland).
A 12-year follow-up study found a 30 percent of the participants underwent androgen deprivation therapy (also known as androgen suppression therapy). The study also found an 81 percent of enhanced risk of heart failure among prostate cancer patients without cardiovascular diseases (CVD) at the start of the study and underwent androgen deprivation therapy. Among men with cardiovascular disease (CVD) at the start of the study, the study shows a 44 percent of enhanced risk of arrhythmia (abnormal and irregular heart rate) and three times enhanced risk of conduction disorder of the heart (electrical impulses of the heart). The study results accounted for risk factors such as tobacco use, body mass index (BMI), prostate-specific antigen levels, hypertension or blood pressure (BP), diabetes or high blood sugar or glucose levels and cardiovascular diseases (CVD).
Researchers say localized prostate cancer patients should consider the effects of the androgen deprivation therapy (ADT) and they should discuss with their doctor. Patients should take steps to modify their lifestyle to reduce the risk and symptoms associated with cardiovascular diseases (CVD) if the person is undergoing androgen deprivation therapy (ADT). The following table shows the survival rates with local or regional prostate cancer without any treatment.
Lead authors of the study were Reina Haque, Ph.D., MPH, research scientist II, Department of Research & Evaluation, Kaiser Permanente Southern California. The study was published August 24, 2017, in the British Journal of Cancer. Title of the article was "Cardiovascular disease risk and androgen deprivation therapy (ADT) in patients with localized prostate cancer: a prospective cohort study."
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.